1. Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller
- Author
-
Molinos-Albert, Luis, Baquero, Eduard, Bouvin-Pley, Mélanie, Lorin, Valerie, Charre, Caroline, Planchais, Cyril, Dimitrov, Jordan, Monceaux, Valérie, Vos, Matthijn, Group, Anrs Visconti, Hocqueloux, Laurent, Berger, Jean-Luc, Seaman, Michael, Braibant, Martine, Avettand-Fenoël, Véronique, Sáez-Cirión, Asier, Mouquet, Hugo, Immunologie humorale - Humoral Immunology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Plateforme technologique Nanoimagerie / Nanoimaging Technological Platform, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Réservoirs viraux et contrôle immunitaire / Viral reservoirs and immune control, HIV, Inflammation et persistance - HIV, Inflammation and Persistence, Hôpital La Source [Orléans] (HLSO), Centre Hospitalier Universitaire de Reims (CHU Reims), Beth Israel Deaconess Medical Center [Boston] (BIDMC), and Harvard Medical School [Boston] (HMS)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; HIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usually unable to counteract autologous viruses escaping the antibody pressure. Nonetheless, bNAbs may contribute to natural HIV-1 control in individuals off antiretroviral therapy (ART). Here, we describe a bNAb B cell lineage elicited in a post-treatment controller (PTC) that exhibits broad seroneutralization and show that a representative antibody from this lineage, EPTC112, targets a quaternary epitope in the glycan-V3 loop supersite of the HIV-1 envelope glycoprotein. The cryo-EM structure of EPTC112 complexed with soluble BG505 SOSIP.664 envelope trimers revealed interactions with N301- and N156-branched N-glycans and the 324GDIR327 V3 loop motif. Although the sole contemporaneous virus circulating in this PTC was resistant to EPTC112, it was potently neutralized by autologous plasma IgG antibodies. Our findings illuminate how cross-neutralizing antibodies can alter the HIV-1 infection course in PTCs and may control viremia off-ART, supporting their role in functional HIV-1 cure strategies.
- Published
- 2023
- Full Text
- View/download PDF